Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Heart attack-related depression puts patients at risk for further cardiovascular emergencies

29.11.2006
New research suggests need for more targeted depression screenings, treatment strategies

People who experience their first-ever bout of depression after having a heart attack are at greater risk for future heart problems than are patients who either don’t become clinically depressed after the medical emergency or who were depressed even before the incident, new research shows.

As a result, new depression-related screening protocols and treatment strategies may be needed to help reduce the likelihood of future heart problems in these patients, according to the research, which appears in the Dec. 5, 2006 edition of the Journal of the American College of Cardiology.

Known as the DepreMI Study, the research was conducted in the Netherlands at University Medical Centre Groningen, part of the University of Groningen. Lead researcher Peter de Jonge, PhD, said the team was seeking to determine whether all types of depression could be considered a direct cause of heart attack. What the group found was a bit surprising.

“We found that only incident (first-time) depression – no other type – was related to a poor prognosis,” said Dr. de Jonge, an assistant professor of internal medicine and psychiatry at the University of Groningen. “In other words, our findings suggest that patients who experience depression after a heart attack, but never before, are at particular risk for future incidents.

“Based on other studies, it appears that standard antidepressive treatment may not be sufficient for this category of patients,” Dr. de Jonge continued. “We feel that especially in these cases, antidepressive treatment should be integrated into cardiac after-care and made a prominent part of the rehabilitation program.”

Standard antidepressive treatment, which frequently includes medications to affect mood, may be insufficient, Dr. de Jonge explained, because incident post-heart attack depression is different than typical depression.

Patients with post-heart attack depression often have survived more severe medical emergencies than other heart attack patients, he said. As a result, these patients may be physically more exhausted and vulnerable than their peers.

“[T]his finding may explain the relatively high effectiveness of psychoeducational interventions, including stress management and relaxation, to prevent cardiac events in coronary artery disease patients,” the researchers state in their manuscript.

For the study, the researchers observed 468 patients hospitalized for heart attack for a mean follow-up period of 2.5 years. Patients were clinically evaluated for depression while in the hospital and again at three months and 12 months post-heart attack. Those with heart attack-related depression experienced more fatal and non-fatal cardiovascular emergencies than did patients who either did not become depressed or who were depressed before having a heart attack.

Based on these findings, Dr. de Jonge said, researchers need to create interventional studies in which non-standard treatments for depression are evaluated in patients with post-heart attack depression to determine which methods are most effective in protecting long-term health.

Roland von Känel, MD, a professor of medicine and head of the psychosomatic division at University Hospital Berne in Switzerland, did not participate in the study, but said it provides important information on “cardiotoxic” subtypes of depression and clues on improving care. Dr. von Känel is the first author of an editorial comment about heart attack and depression that will be published in conjunction with the new research.

“Given what we now know, I believe that screening for depression should be part of today’s clinical practice in a cardiology setting any time a patient is referred to the ICU with a heart attack,” Dr. von Känel said. “Depressed patients should be treated with counseling, referral to a psychotherapist and/or antidepressant medication – preferably an SSRI (selective serotonin reuptake inhibitor) – depending upon the severity of their depression.”

SSRI medications seek to improve mood by slowing the reuptake of the neurotransmitter serotonin in the brain; the medications have been shown to be safe and efficient in patients with heart disease. Serotonin affects emotions, mood and thought.

“In addition, improving social support, establishing a physical exercise regimen and addressing psychosocial issues, such as job situation, family conflicts and stress-causing health concerns, also may be necessary,” Dr. von Känel said. “All of these things will work together to benefit quality of life, improve adherence to cardiac treatment and reduce health care costs.”

The next steps, Dr. von Känel said, are to conduct additional research to ensure that patients receive the most effective treatments and to determine which of these treatments improve hard cardiovascular end-points, such as recurrent heart attack.

“There is no study showing to date that treatment of depression with psychotherapy improves cardiac or overall survival,” he said. “Non-randomized studies show, however, that SSRIs may benefit depressed patients after a heart attack in terms of improving cardiovascular outcome. A randomized double-blind, placebo-controlled trial with an antidepressant as well as an individually tailored psychotherapeutic intervention study are badly needed to resolve these issues.”

Amy Murphy | EurekAlert!
Further information:
http://www.acc.org

More articles from Health and Medicine:

nachricht Dengue takes low and slow approach to replication
12.01.2018 | Duke University

nachricht Fast food makes the immune system more aggressive in the long term
12.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

Im Focus: Autoimmune Reaction Successfully Halted in Early Stage Islet Autoimmunity

Scientists at Helmholtz Zentrum München have discovered a mechanism that amplifies the autoimmune reaction in an early stage of pancreatic islet autoimmunity prior to the progression to clinical type 1 diabetes. If the researchers blocked the corresponding molecules, the immune system was significantly less active. The study was conducted under the auspices of the German Center for Diabetes Research (DZD) and was published in the journal ‘Science Translational Medicine’.

Type 1 diabetes is the most common metabolic disease in childhood and adolescence. In this disease, the body's own immune system attacks and destroys the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fachtagung analytica conference 2018

15.01.2018 | Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

 
Latest News

Black hole spin cranks-up radio volume

15.01.2018 | Physics and Astronomy

A matter of mobility: multidisciplinary paper suggests new strategy for drug discovery

15.01.2018 | Life Sciences

New method to map miniature brain circuits

15.01.2018 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>